Miami is the No. 2 most sex-curious city in America—here's what beat it
A recent ZipHealth survey, the ' Libido Index ', delved into Google search data from all 50 states and major U.S. cities to determine how sexual health and libido varies across the country and the results are startling. ZipHealth, a US-based online pharmacy for
FDA-approved medication, including options for sexual health, zeroed in on 303 search terms across 50 states and 50 US cities.
Per capita, New York, Washington, and Virginia have the highest output of libido-related searches nationwide, while Atlanta, Miami, and Minneapolis hold the top three urban rankings for investigations on sex drive and sexual health. 'What can I do to increase my sex drive female' is the most frequently searched phrase, sitting at the top of the list in eight states: Alabama, Arkansas, Kentucky, Louisiana, North Carolina, Oklahoma, Texas, and Wisconsin.
'Over the counter ED pills', 'testosterone supplements', 'why doesn't my wife want sex', 'average sex drive of a woman' and 'sex recession' all topped the search list as well.
When it comes to urban enclaves with the most digital curiosity surrounding the topic of libidos, Atlanta ranked No. 1, with Miami coming in second. Minneapolis, Seattle, Denver, Boston, Tampa (coming in at number seven), Las Vegas, Baltimore and Sacramento all made the top 10 for searches around sexual health and libido.
Navigating sexual health and wellness can be a tricky endeavor, if not a highly personal and emotional one. ZipHealth's "Libido Index" might be a conduit for determining what is important to people across the country, as well as highlighting the complicated dynamics of relationships, mental health and emotional wellbeing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
VIVAZEN Applauds Federal Action to Ban Dangerous Synthetic 7-OH and Reaffirms Support for Science-Driven Kratom Reform
PHOENIX, AZ, July 29, 2025 (EZ Newswire) -- VIVAZEN, opens new tab, a leading natural wellness company, issued the following statement today commending the U.S. Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Drug Enforcement Administration (DEA) for taking decisive action this week to protect consumers from the dangerous synthetic 7-hydroxymitragynine (7-OH) and to establish a clear regulatory distinction between adulterated products and natural kratom. 'As someone who has experienced the benefits of kratom firsthand, I've long been an advocate for ensuring that this important botanical is safely and responsibly available to customers. This is a milestone for consumer safety, scientific integrity, and public health,' said Steve Curtis, CEO of VIVAZEN. 'We fully support the FDA and HHS in taking this courageous action in drawing a clear line between the naturally occurring alkaloids in kratom and the synthetic opioid-like compound 7-hydroxymitragynine. These are not the same substance, and conflating them has harmed consumers and held back meaningful botanical research. We further urge the agency to use the full extent of its power to immediately remove 7-OH products from store shelves.' 7-hydroxymitragynine, often produced by chemically oxidizing kratom's primary alkaloid, mitragynine using industrial oxidants like bleach and pool shock, can be present at potent and dangerous concentrations in adulterated products that falsely claim to be 'kratom.' In contrast, natural kratom leaves contain only trace amounts of 7-OH, if any, and have been safely used by millions of Americans. VIVAZEN has long been at the forefront of science-first kratom formulation, ensuring all of its products are rigorously tested, contain no synthetic alkaloids, and comply with evolving state and federal safety standards. 'What's happening now is the beginning of regulatory maturity,' said Curtis. 'FDA's own data now confirms the safety and tolerability of mitragynine at levels up to 140 mg. NIH-funded studies also show kratom enhances, rather than suppresses, respiratory activity, exactly the opposite of synthetic 7-OH. This bifurcation is necessary and overdue.' VIVAZEN encourages the following actions by HHS and FDA: 'Consumers deserve clean, transparent, and trustworthy products,' Curtis added. 'At VIVAZEN, we've built our brand on safety and integrity, and we welcome this renewed focus on scientific truth. We look forward to working with policymakers and regulators to protect the future of kratom and the millions who rely on it.' About VIVAZEN For over a decade, VIVAZEN has delivered trusted, high-quality botanical supplements that provide people with functional wellness without compromise. Rooted in centuries of herbal wisdom and backed by modern innovation, VIVAZEN is a functional, feel-good alternative for those who want to live—and feel—on their own terms. Join the millions who trust VIVAZEN to Feel Great™ naturally, and visit opens new tab. Media Contact Paloma Lehfeldtpress@ ### SOURCE: VIVAZEN Copyright 2025 EZ Newswire See release on EZ Newswire
Reuters
2 hours ago
- Reuters
Leading Botanical Science and Health Advocacy Groups Applaud Federal Action to Ban Synthetic 7-OH and Clear Path for Kratom Reform
CLEVELAND, OH, July 29, 2025 (EZ Newswire) -- Botanicals for Better Health and Wellness (BBHW), opens new tab and the Scientific Association for Botanical Education and Research (SABER), opens new tab issued the following joint statement today, commending the U.S. Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Drug Enforcement Administration (DEA) for taking decisive action to safeguard public health by targeting the synthetic opioid-like compound 7-hydroxymitragynine (7-OH) and formally distinguishing it from the natural botanical kratom. BBHW and SABER are publicly supporting this bifurcated regulatory approach as a 'scientifically grounded step forward for consumer safety and botanical innovation.' The announcement, on the morning of July 29, 2025, was delivered by HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Dr. Marty Makary, signaling a coordinated federal response to the widespread sale of mislabeled and chemically altered products masquerading as kratom that pose significant health risks. 'This is a long-overdue correction,' said Dr. Paloma Lehfeldt, medical advisor to Botanicals for Better Health and Wellness (BBHW). 'By clearly separating the natural botanical kratom from synthetic compounds like 7-hydroxymitragynine, which have been misleadingly marketed under the same name, federal agencies are addressing a major source of consumer confusion. These actions will protect consumers while preserving access to a culturally significant botanical with potential therapeutic value, while moving toward a more rational, evidence-informed regulatory approach.' SABER, a coalition of scientists and educators advancing evidence-based botanical research, applauded the bifurcation of the botanical kratom from synthetic drugs like 7-OH. 7-hydroxymitragynine, a synthetic drug manufactured using industrial oxidizers, exhibits high opioid receptor affinity and has been linked to respiratory depression and toxicity. It is not found in natural kratom leaves at physiologically relevant levels. By contrast, kratom's primary alkaloid, mitragynine, is a partial receptor agonist with low abuse potential, and recent FDA-funded studies have confirmed its favorable safety profile at doses up to 140 mg in healthy adults. 'For too long, the conversation around kratom has been polluted by bad actors and misinformation,' said Dr. Paula Brown, a member of the SABER steering committee and director of natural health and food products research at the British Columbia Institute of Technology (BCIT). 'FDA's data now supports what scientists have known for years: kratom is not a narcotic, and 7-OH is not a natural constituent of the plant. Differentiating them is both scientifically necessary and ethically urgent.' BBHW and SABER are calling on FDA to finalize the following actions: 'This is what responsible botanical regulation looks like,' said Dr. Mary Hardy, MD, SABER steering committee member and integrative medicine researcher. 'Science, not stigma, must guide public health policy.' About Scientific Association for Botanical Education and Research (SABER) The Scientific Association for Botanical Education and Research (SABER) is a nonprofit organization dedicated to advancing scientific understanding, regulation, and safe access to botanicals. Through research partnerships, policy advocacy, and public education, SABER works to ensure that natural products are studied responsibly, used safely, and regulated appropriately. To learn more, visit Media Contact Paloma Lehfeldtinfo@ ### SOURCE: Scientific Association for Botanical Education and Research (SABER) Copyright 2025 EZ Newswire See release on EZ Newswire
Reuters
2 hours ago
- Reuters
American Kratom Association Praises Secretary Kennedy and Commissioner Makary for Bold Action to Recommend Scheduling of Dangerous 7-OH Products
WASHINGTON, DC, July 29, 2025 (EZ Newswire) -- American Kratom Association (AKA), opens new tab today applauded Secretary Robert Kennedy and FDA Commissioner Dr. Marty Makary for their decisive and science-driven recommendation to classify 7-hydroxymitragynine (7-OH) as a Schedule I substance under the federal Controlled Substances Act. This bold step is a critical milestone in protecting public health and consumer safety from dangerous synthetic products that masquerade as natural kratom. 'Secretary Kennedy and Commissioner Makary have shown exceptional leadership in confronting one of the most urgent public health threats related to mislabeled, manipulated psychoactive substances,' said Mac Haddow, senior fellow on public policy for the American Kratom Association. 'These 7-OH products are not kratom. They are chemically altered substances that carry potent opioid-like effects and pose an imminent threat to consumers. This move sends a clear and long-overdue message: the safety of the American public comes first.' 7-hydroxymitragynine is a metabolite — not a naturally occurring substance in the kratom plant — and occurs during the drying of kratom leaves at extremely low levels, typically less than 0.01%. However, unscrupulous manufacturers have exploited chemical manipulation to create concentrated 7-OH products that far exceed natural levels, creating high-potency, opioid-like effects that are addictive and potentially lethal. These products are often falsely marketed under the kratom name, misleading consumers and damaging the reputation of natural kratom, which has a vastly different safety profile. The American Kratom Association has worked tirelessly to educate policymakers, regulators, and the public on the difference between natural kratom products and chemically manipulated 7-OH formulations. The AKA has advocated for state-based Kratom Consumer Protection Acts (KCPA) to ban the sale of adulterated and dangerously enhanced products. This federal scheduling recommendation is a landmark development that supports those efforts and establishes a much-needed national framework to protect consumers. 'The FDA's own research shows that natural kratom has a relatively low potential for abuse and may offer harm-reduction benefits when used responsibly,' Haddow continued. 'It is the synthetic manipulation of 7-OH that has created the danger. The action by Secretary Kennedy and Commissioner Makary is not only scientifically justified, it is morally imperative.' The AKA urges swift action by the Drug Enforcement Administration (DEA) to initiate the rule-making process to schedule synthetically manipulated 7-hydroxymitragynine and to make clear that such action does not impact the legal status of natural kratom or its primary alkaloids, mitragynine and unaltered 7-OH occurring within the plant matrix. The goal is to eliminate the threat posed by rogue products while preserving access to safe, regulated kratom. 'We look forward to working with federal agencies and state policymakers to ensure that safe access to natural kratom is protected, while these dangerous imposters are removed from the marketplace,' said Haddow. Note: The FDA also released "Hiding in Plain Sight: 7-OH Products, opens new tab" to help educate the public. About American Kratom Association (AKA) American Kratom Association (AKA) is a consumer-based, nonprofit organization, focused on furthering the latest science as guidance for kratom public policy. AKA works to give a voice to millions of Americans by fighting to protect their rights to access safe and natural kratom. For more information, visit and learn more at Media Contact Mac Haddowpress@ ### SOURCE: American Kratom Association (AKA) Copyright 2025 EZ Newswire See release on EZ Newswire
